Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 128 articles:
HTML format



Single Articles


    April 2020
  1. LONG M, Zhu Y, Chen Z, Lin S, et al
    Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1alpha and microRNA-146a.
    J Clin Endocrinol Metab. 2020 Apr 18. pii: 5821525. doi: 10.1210.
    PubMed     Abstract available


    February 2020
  2. VOGEL T, Wendler J, Frank-Raue K, Kreissl MC, et al
    Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology.
    J Clin Endocrinol Metab. 2020 Feb 19. pii: 5740219. doi: 10.1210.
    PubMed     Abstract available


    October 2019
  3. ASARE EA, Perrier ND
    Letter to the Editor: "An Analysis of the American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2019 Oct 28. pii: 5607922. doi: 10.1210.
    PubMed    


  4. HUGEN N, Sloot YJE, Netea-Maier RT, van de Water C, et al
    Divergent metastatic patterns between subtypes of thyroid carcinoma results from the nationwide Dutch pathology registry.
    J Clin Endocrinol Metab. 2019 Oct 23. pii: 5602698. doi: 10.1210.
    PubMed     Abstract available


    August 2019
  5. ESFANDIARI NH, Hughes DT, Reyes-Gastelum D, Ward KC, et al
    Factors Associated with Diagnosis and Treatment of Thyroid Microcarcinomas.
    J Clin Endocrinol Metab. 2019 Aug 15. pii: 5550196. doi: 10.1210/jc.2019-01219.
    PubMed     Abstract available


    July 2019
  6. CHONG ST, Tan KM, Kok CYL, Guan SP, et al
    IL13RA2 is differentially regulated in Papillary Thyroid Carcinoma versus Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2019 Jul 10. pii: 5530249. doi: 10.1210/jc.2019-00040.
    PubMed     Abstract available


    May 2019
  7. RAUE F, Bruckner T, Frank-Raue K
    Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.
    J Clin Endocrinol Metab. 2019 May 30. pii: 5506437. doi: 10.1210/jc.2019-00516.
    PubMed     Abstract available


  8. NISHIKAWA Y, Kohno A, Takahashi Y, Suzuki C, et al
    Stable Iodine Distribution Among Children After the 2011 Fukushima Nuclear Disaster in Japan: An Observational Study.
    J Clin Endocrinol Metab. 2019;104:1658-1666.
    PubMed     Abstract available


    April 2019
  9. SAPUPPO G, Tavarelli M, Belfiore A, Vigneri R, et al
    Response to Letter to the Editor: [Time to Separate Persistent from Recurrent Differentiated Thyroid Cancer: Different Conditions with Different outcomes].
    J Clin Endocrinol Metab. 2019 Apr 24. pii: 5476510. doi: 10.1210/jc.2019-00851.
    PubMed    


  10. BURMEISTER LA, Drake T
    "Letter to the Editor: [Time to Separate Persistent from Recurrent Differentiated Thyroid Cancer: Different Conditions with Different outcomes]".
    J Clin Endocrinol Metab. 2019 Apr 24. pii: 5476515. doi: 10.1210/jc.2019-00634.
    PubMed    


  11. MA B, Jiang H, Wen D, Hu J, et al
    Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer.
    J Clin Endocrinol Metab. 2019 Apr 3. pii: 5425396. doi: 10.1210/jc.2018-02686.
    PubMed     Abstract available


    March 2019
  12. GIANNINI R, Moretti S, Ugolini C, Macerola E, et al
    Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like.
    J Clin Endocrinol Metab. 2019 Mar 18. pii: 5381919. doi: 10.1210/jc.2018-01167.
    PubMed     Abstract available


  13. DEANDREA M, Trimboli P, Garino F, Mormile A, et al
    Long Term Efficacy of a Single Session RFA of Benign Thyroid Nodules: A Longitudinal 5-Year Observational Study.
    J Clin Endocrinol Metab. 2019 Mar 12. pii: 5372729. doi: 10.1210/jc.2018-02808.
    PubMed     Abstract available


  14. COLOMBO C, De Leo S, Di Stefano M, Vannucchi G, et al
    Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
    J Clin Endocrinol Metab. 2019;104:779-784.
    PubMed     Abstract available


    February 2019
  15. LI J, An C, Zheng H, Lei T, et al
    Leukocyte telomere length and risk of papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2019 Feb 28. pii: 5365821. doi: 10.1210/jc.2018-02471.
    PubMed     Abstract available


  16. BARRES B, Kelly A, Kwiatkowski F, Batisse-Lignier M, et al
    Stimulated thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    J Clin Endocrinol Metab. 2019 Feb 20. pii: 5342942. doi: 10.1210/jc.2018-02680.
    PubMed     Abstract available


    November 2018
  17. WIRTH LJ
    Still Perfecting Radioiodine in Thyroid Cancer, After All These Years.
    J Clin Endocrinol Metab. 2018 Nov 19. pii: 5185197. doi: 10.1210/jc.2018-02437.
    PubMed    


  18. HATCH M, Brenner AV, Cahoon EK, Drozdovitch V, et al
    Thyroid Cancer and Benign Nodules after Exposure In Utero to Fallout from Chernobyl.
    J Clin Endocrinol Metab. 2018 Nov 16. pii: 5184192. doi: 10.1210/jc.2018-00847.
    PubMed     Abstract available


  19. LEENHARDT L, Leboulleux S, Bournaud C, Zerdoud S, et al
    Recombinant thyrotropin vs levothyroxine withdrawal in 131I therapy of N1 thyroid cancer: a large matched cohort study (ThyrNod).
    J Clin Endocrinol Metab. 2018 Nov 5. pii: 5155461. doi: 10.1210/jc.2018-01589.
    PubMed     Abstract available


    October 2018
  20. HAYMART MR, Banerjee M, Reyes-Gastelum D, Caoili E, et al
    Thyroid Ultrasound and the Increase in Diagnosis of Low-risk Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 Oct 16. pii: 5128913. doi: 10.1210/jc.2018-01933.
    PubMed     Abstract available


  21. GRANI G, Lamartina L, Ascoli V, Bosco D, et al
    Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the "right" TIRADS.
    J Clin Endocrinol Metab. 2018 Oct 8. pii: 5115830. doi: 10.1210/jc.2018-01674.
    PubMed     Abstract available


    September 2018
  22. ALZAHRANI AS, Alswailem M, Moria Y, Almutairi R, et al
    Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy and Outcome.
    J Clin Endocrinol Metab. 2018 Sep 28. pii: 5107762. doi: 10.1210/jc.2018-01690.
    PubMed     Abstract available


  23. DUNN LA, Sherman EJ, Baxi SS, Tchekmedyian V, et al
    Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
    J Clin Endocrinol Metab. 2018 Sep 25. pii: 5105931. doi: 10.1210/jc.2018-01478.
    PubMed     Abstract available


    August 2018
  24. PARK SY, Cho YY, Kim HI, Choe JH, et al
    Clinical validation of the prognostic stage groups of the eighth edition TNM staging for medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Aug 17. pii: 5075160. doi: 10.1210/jc.2018-01386.
    PubMed     Abstract available


  25. BOUCAI L, Falcone J, Ukena J, Coombs CC, et al
    Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival.
    J Clin Endocrinol Metab. 2018 Aug 17. pii: 5075165. doi: 10.1210/jc.2018-00803.
    PubMed     Abstract available


  26. HWANGBO Y, Lee EK, Son HY, Im SW, et al
    Genome-wide Association Study Reveals Distinct Genetic Susceptibility of Thyroid Nodules from Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 Aug 6. pii: 5066513. doi: 10.1210/jc.2017-02439.
    PubMed     Abstract available


    July 2018
  27. ZHANG X, Wang C, Lin Y
    Pilot Dose Comparison of Apatinib in Chinese Progressive Radioiodine Refractory Differentiated Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2018 Jul 20. pii: 5056320. doi: 10.1210/jc.2018-00381.
    PubMed     Abstract available


  28. KLUBO-GWIEZDZINSKA J, Wartofsky L
    Commentary on: "Gene Expression Classifier versus Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules".
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055545. doi: 10.1210/jc.2018-01081.
    PubMed    


  29. TURNBULL C, Loveday C, Izatt L, Ellard S, et al
    Response to Letter to the Editor regarding : "p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer" from Andreas Machens and Henning Dralle.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055548. doi: 10.1210/jc.2018-01094.
    PubMed    


  30. JABER T, Waguespack SG, Cabanillas ME, Elbanan M, et al
    Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055540. doi: 10.1210/jc.2018-00612.
    PubMed     Abstract available


  31. PANDYA A, Caoili EM, Jawad-Makki F, Wasnik AP, et al
    Limitations of the 2015 ATA Guidelines for Prediction of Thyroid Cancer: A Review of 1,947 Consecutive Aspirations.
    J Clin Endocrinol Metab. 2018 Jul 3. pii: 5047770. doi: 10.1210/jc.2018-00792.
    PubMed     Abstract available


  32. CHERELLA CE, Feldman HA, Hollowell M, Richman DM, et al
    Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047287. doi: 10.1210/jc.2018-00895.
    PubMed     Abstract available


    June 2018
  33. MACHENS A, Dralle H
    Letter to the Editor: "p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer".
    J Clin Endocrinol Metab. 2018 Jun 26. pii: 5043208. doi: 10.1210/jc.2018-00906.
    PubMed    


  34. KIM K, Kim IJ, Pak K, Kim SJ, et al
    Evaluation of bone mineral density using DXA and central QCT in postmenopausal patients under thyrotropin suppressive therapy.
    J Clin Endocrinol Metab. 2018 Jun 21. pii: 5041930. doi: 10.1210/jc.2017-02704.
    PubMed     Abstract available



  35. CORRIGENDUM FOR "DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma".
    J Clin Endocrinol Metab. 2018 Jun 4. pii: 5032648. doi: 10.1210/jc.2018-01190.
    PubMed    


  36. SADOWSKI SM, Pusztaszeri M, Brulhart-Meynet MC, Petrenko V, et al
    Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2018;103:2189-2198.
    PubMed     Abstract available


    May 2018
  37. PARK J, Blackburn BE, Ganz PA, Rowe K, et al
    Risk Factors for Cardiovascular Disease among Thyroid Cancer Survivors: Findings from the Utah Cancer Survivors Study.
    J Clin Endocrinol Metab. 2018 May 29. pii: 5005948. doi: 10.1210/jc.2017-02629.
    PubMed     Abstract available


  38. CASTRONEVES LA, Coura Filho G, de Freitas RMC, Salles R, et al
    Comparison of 68Ga PET/CT to other imaging studies in Medullary Thyroid Cancer: superiority in detecting bone metastases.
    J Clin Endocrinol Metab. 2018 May 28. pii: 5005944. doi: 10.1210/jc.2018-00193.
    PubMed     Abstract available


  39. MARLOW LA, Rohl SD, Miller JL, Knauf JA, et al
    Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
    J Clin Endocrinol Metab. 2018 May 25. pii: 5003409. doi: 10.1210/jc.2017-01845.
    PubMed     Abstract available


  40. MACFARLAND SP, Bauer AJ, Adzick NS, Surrey LF, et al
    Disease Burden and Outcome in Pediatric and Young Adults with Concurrent Graves Disease and Differentiated Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 May 18. pii: 4998998. doi: 10.1210/jc.2018-00026.
    PubMed     Abstract available


  41. BANERJEE M, Reyes-Gastelum D, Haymart MR
    Treatment-free Survival in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 May 16. pii: 4996515. doi: 10.1210/jc.2018-00511.
    PubMed     Abstract available


  42. NICOLSON NG, Murtha TD, Dong W, Paulsson JO, et al
    Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology.
    J Clin Endocrinol Metab. 2018 May 2. pii: 4990776. doi: 10.1210/jc.2018-00277.
    PubMed     Abstract available


  43. LIVHITS M
    Response to Letter to the Editor: "Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015".
    J Clin Endocrinol Metab. 2018;103:2073.
    PubMed    


  44. YLLI D, Burman KD, Van Nostrand D, Wartofsky L, et al
    Eliminating the Age Cutoff in Staging of Differentiated Thyroid Cancer: The Safest Road?
    J Clin Endocrinol Metab. 2018;103:1813-1817.
    PubMed     Abstract available


    April 2018
  45. TRAN B DR., Roshan D Mr., Abraham E Dr., Wang L Dr., et al
    An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970148. doi: 10.1210/jc.2017-02551.
    PubMed     Abstract available


  46. MAINO F, Forleo R, Martinelli M, Fralassi N, et al
    Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970151. doi: 10.1210/jc.2018-00274.
    PubMed     Abstract available


  47. JABER T, Hyde SM, Cote GJ, Grubbs EG, et al
    A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    J Clin Endocrinol Metab. 2018;103:1269-1272.
    PubMed     Abstract available


    March 2018
  48. KITAHARA CM, Farkas DKR, Jorgensen JOL, Cronin-Fenton D, et al
    Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951500. doi: 10.1210/jc.2017-02599.
    PubMed     Abstract available


  49. LIVHITS MJ, Kuo EJ, Leung AM, Rao J, et al
    Gene Expression Classifier versus Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951503. doi: 10.1210/jc.2017-02754.
    PubMed     Abstract available


  50. LOVEDAY C, Josephs K, Chubb D, Gunning A, et al
    p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951497. doi: 10.1210/jc.2017-02529.
    PubMed     Abstract available


  51. WU D, Guan H
    Letter to the Editor: "Decreasing use of radioactive iodine for low risk thyroid cancer in California, 1999-2015".
    J Clin Endocrinol Metab. 2018 Mar 13. pii: 4931670. doi: 10.1210/jc.2018-00333.
    PubMed    


  52. GANNON AW, Langer JE, Bellah R, Ratcliffe S, et al
    Diagnostic Accuracy of Ultrasound with Color Flow Doppler in Children with Thyroid Nodules.
    J Clin Endocrinol Metab. 2018 Mar 12. pii: 4931064. doi: 10.1210/jc.2017-02464.
    PubMed     Abstract available


    February 2018
  53. WASSERMAN JD, Sabbaghian N, Fahiminiya S, Chami R, et al
    DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Feb 21. pii: 4893697. doi: 10.1210/jc.2017-02698.
    PubMed     Abstract available


  54. SAMUELS SL, Surrey LF, Hawkes CP, Amberge M, et al
    Characteristics of Follicular Variant Papillary Thyroid Carcinoma in a Pediatric Cohort.
    J Clin Endocrinol Metab. 2018 Feb 8. pii: 4844750. doi: 10.1210/jc.2017-02454.
    PubMed     Abstract available


  55. PERSICHETTI A, Di Stasio E, Guglielmi R, Bizzarri G, et al
    Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems. A Prospective Study.
    J Clin Endocrinol Metab. 2018 Feb 1. pii: 4834029. doi: 10.1210/jc.2017-01708.
    PubMed     Abstract available


    January 2018
  56. GIORDANO TJ, Haugen B, Sherman SI, Shah MH, et al
    Pioglitazone Therapy of PAX8-PPARgamma Fusion Protein Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Jan 24. pii: 4822913. doi: 10.1210/jc.2017-02533.
    PubMed     Abstract available


  57. TARABICHI M, Antoniou A, Le Pennec S, Gacquer D, et al
    Distinctive desmoplastic 3D morphology associated with BRAFV600E in papillary thyroid cancers.
    J Clin Endocrinol Metab. 2018 Jan 12. pii: 4801233. doi: 10.1210/jc.2017-02279.
    PubMed     Abstract available


  58. RAUE F, Dralle H, Machens A, Bruckner T, et al
    Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium.
    J Clin Endocrinol Metab. 2018;103:235-243.
    PubMed     Abstract available


    December 2017
  59. PRATHEESHKUMAR P, Siraj AK, Divya SP, Parvathareddy SK, et al
    Downregulation of SKP2 in papillary thyroid cancer acts synergistically with TRAIL on inducing apoptosis via ROS.
    J Clin Endocrinol Metab. 2017 Dec 28. pii: 4780811. doi: 10.1210/jc.2017-02178.
    PubMed     Abstract available


  60. PARK KW, Wu JX, Du L, Leung AM, et al
    Decreasing use of radioactive iodine for low risk thyroid cancer in California, 1999-2015.
    J Clin Endocrinol Metab. 2017 Dec 15. pii: 4743227. doi: 10.1210/jc.2017-02269.
    PubMed     Abstract available


  61. SHIMURA H, Sobue T, Takahashi H, Yasumura S, et al
    Findings of thyroid ultrasound examination within three years after the Fukushima Nuclear Power Plant accident: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2017 Dec 14. pii: 4630428. doi: 10.1210/jc.2017-01603.
    PubMed     Abstract available


  62. RITTER A, Bachar G, Hirsch D, Benbassat C, et al
    Natural History of Contralateral Nodules after Lobectomy in Patients with Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017 Dec 12. pii: 4731740. doi: 10.1210/jc.2017-01616.
    PubMed     Abstract available


  63. SHAH S, Boucai L
    Effect of Age on Response to Therapy and Mortality in Patients with Thyroid Cancer at High-Risk of Recurrence.
    J Clin Endocrinol Metab. 2017 Dec 6. pii: 4693942. doi: 10.1210/jc.2017-02255.
    PubMed     Abstract available


  64. VAN DER TUIN K, Tops CMJ, Adank MA, Cobben JM, et al
    CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2017;102:4534-4540.
    PubMed     Abstract available


  65. KIM HI, Jang HW, Ahn HS, Ahn S, et al
    High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance.
    J Clin Endocrinol Metab. 2017 Dec 1. pii: 4677373. doi: 10.1210/jc.2017-01775.
    PubMed     Abstract available


    November 2017
  66. WATANABE N, Narimatsu H, Noh JY, Iwaku K, et al
    Long-term outcomes of 107 cases of primary thyroid MALT lymphoma at a single medical institution in Japan.
    J Clin Endocrinol Metab. 2017 Nov 20. doi: 10.1210/jc.2017-01478.
    PubMed     Abstract available


  67. KLEIN HESSELINK EN, Zafon C, Villalmanzo N, Iglesias C, et al
    Increased global DNA hypomethylation in distant metastatic and dedifferentiated thyroid cancer.
    J Clin Endocrinol Metab. 2017 Nov 20. doi: 10.1210/jc.2017-01613.
    PubMed     Abstract available


  68. HE H, Li W, Liyanarachchi S, Wang Y, et al
    The role of NRG1 in the predisposition to papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01798.
    PubMed     Abstract available


  69. MAZZIOTTI G, Formenti AM, Frara S, Olivetti R, et al
    HIGH PREVALENCE OF RADIOLOGICAL VERTEBRAL FRACTURES IN WOMEN ON TSH-SUPPRESSIVE THERAPY FOR THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01986.
    PubMed     Abstract available


  70. HIRSCH D, Gorshtein A, Robenshtok E, Masri-Iraqi H, et al
    Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer with Loforegional Persistent Disease.
    J Clin Endocrinol Metab. 2017 Nov 3. doi: 10.1210/jc.2017-01790.
    PubMed     Abstract available


  71. CASEY RT, Warren AY, Martin JE, Challis BG, et al
    Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.
    J Clin Endocrinol Metab. 2017;102:4013-4022.
    PubMed     Abstract available


    October 2017

  72. CORRIGENDUM FOR Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017 Oct 24. doi: 10.1210/jc.2017-02312.
    PubMed    


  73. ANGELL TE, Vyas C, Medici M, Wang Z, et al
    Differential Growth Rates of Benign versus Malignant Thyroid Nodules.
    J Clin Endocrinol Metab. 2017 Oct 12. doi: 10.1210/jc.2017-01832.
    PubMed     Abstract available


  74. PRASONGSOOK N, Kumar A, Chintakuntlawar AV, Foote RL, et al
    Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Oct 5. doi: 10.1210/jc.2017-01180.
    PubMed     Abstract available


    September 2017
  75. VOSS RK, Grubbs EG
    Response to Letter: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3559.
    PubMed    


  76. CASTINETTI F, Whollk N
    Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3557-3558.
    PubMed    


  77. COTE GJ, Evers C, Hu MI, Grubbs EG, et al
    Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017;102:3591-3599.
    PubMed     Abstract available


  78. VIOLA D, Giani C, Mazzeo S, Ugolini C, et al
    KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.
    J Clin Endocrinol Metab. 2017;102:3091-3096.
    PubMed     Abstract available


    August 2017
  79. DOS REIS MB, Barros-Filho MC, Marchi FA, Beltrami CM, et al
    Prognostic classifier based on genome-wide DNA methylation profiling in well-differentiated thyroid tumors.
    J Clin Endocrinol Metab. 2017 Aug 16. doi: 10.1210/jc.2017-00881.
    PubMed     Abstract available


    July 2017
  80. FRENCH JD, Haugen BR
    Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies?
    J Clin Endocrinol Metab. 2017;102:2131-2132.
    PubMed    


    June 2017
  81. SZCZEPANEK-PARULSKA E, Zybek-Kocik A, Wartofsky L, Ruchala M, et al
    Thyroid hemiagenesis: incidence, clinical significance and genetic background.
    J Clin Endocrinol Metab. 2017 Jun 28. doi: 10.1210/jc.2017-00784.
    PubMed     Abstract available


  82. ROSSFELD KK, Justiniano SE, Ding H, Gong L, et al
    Biological evaluation of a novel fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model.
    J Clin Endocrinol Metab. 2017 Jun 7. doi: 10.1210/jc.2017-00573.
    PubMed     Abstract available


  83. WANG F, Yu X, Shen X, Zhu G, et al
    The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Jun 5. doi: 10.1210/jc.2017-00277.
    PubMed     Abstract available


  84. MATHIESEN JS, Habra MA, Bassett JHD, Choudhury SM, et al
    Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
    J Clin Endocrinol Metab. 2017;102:2069-2074.
    PubMed     Abstract available


  85. MOMESSO DP, Tuttle RM
    Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    J Clin Endocrinol Metab. 2017;102:2115-2116.
    PubMed    


  86. GIOVANELLA L, Cosma C, Plebani M
    Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    J Clin Endocrinol Metab. 2017;102:2113-2114.
    PubMed    


    May 2017
  87. LEE JJ, Wang TY, Liu CL, Chien MN, et al
    Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 May 26. doi: 10.1210/jc.2017-00346.
    PubMed     Abstract available


  88. VOSS RK, Feng L, Lee JE, Perrier ND, et al
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness
    J Clin Endocrinol Metab. 2017 May 9. doi: 10.1210/jc.2017-00317.
    PubMed     Abstract available


  89. IMAIZUMI M, Ohishi W, Nakashima E, Sera N, et al
    Thyroid dysfunction and autoimmune thyroid diseases among atomic-bomb survivors exposed in childhood.
    J Clin Endocrinol Metab. 2017 May 1. doi: 10.1210/jc.2017-00102.
    PubMed     Abstract available


  90. ELISEI R, Binchi F, Matrone A
    Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    J Clin Endocrinol Metab. 2017;102:1785-1786.
    PubMed    


  91. GIOVANELLA L, Ceriani L, Trimboli P
    Letter to the Editor: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    J Clin Endocrinol Metab. 2017;102:1783-1784.
    PubMed    


    April 2017
  92. PAPALEONTIOU M, Hughes DT, Guo C, Banerjee M, et al
    Population-Based Assessment of Complications following Surgery for Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 28. doi: 10.1210/jc.2017-00255.
    PubMed     Abstract available


  93. WASSNER AJ, Della Vecchia M, Jarolim P, Feldman HA, et al
    Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 10. doi: 10.1210/jc.2017-00286.
    PubMed     Abstract available


    March 2017
  94. CAHOON EK, Nadirov EA, Polanskaya ON, Yauseyenka VV, et al
    Risk of thyroid nodules in residents of Belarus exposed to Chernobyl fallout as children and adolescents.
    J Clin Endocrinol Metab. 2017 Mar 22. doi: 10.1210/jc.2016-3842.
    PubMed     Abstract available


  95. LUBIN JH, Adams MJ, Shore R, Holmberg E, et al
    Thyroid cancer following childhood low dose radiation exposure: a pooled analysis of nine cohorts.
    J Clin Endocrinol Metab. 2017 Mar 8. doi: 10.1210/jc.2016-3529.
    PubMed     Abstract available


  96. MELO M, Gaspar da Rocha A, Batista R, Vinagre J, et al
    TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2785.
    PubMed     Abstract available


  97. KWON H, Oh HS, Kim M, Park S, et al
    Active Surveillance for Patients with Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea.
    J Clin Endocrinol Metab. 2017 Mar 3. doi: 10.1210/jc.2016-4026.
    PubMed     Abstract available


    February 2017
  98. KIM TH, Ki CS, Kim HS, Kim K, et al
    Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations.
    J Clin Endocrinol Metab. 2017 Feb 28. doi: 10.1210/jc.2016-3434.
    PubMed     Abstract available


  99. KHAN NE, Bauer AJ, Schultz KA, Doros L, et al
    Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.
    J Clin Endocrinol Metab. 2017 Feb 2. doi: 10.1210/jc.2016-2954.
    PubMed     Abstract available


    January 2017
  100. CHOKSI P, Papaleontiou M, Guo C, Worden F, et al
    Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.
    J Clin Endocrinol Metab. 2017 Jan 25. doi: 10.1210/jc.2016-3906.
    PubMed     Abstract available


  101. PARK S, Jeon MJ, Song E, Oh HS, et al
    Clinical Features of Early and Late Postoperative Hypothyroidism after Lobectomy.
    J Clin Endocrinol Metab. 2017 Jan 11. doi: 10.1210/jc.2016-3597.
    PubMed     Abstract available


    December 2016
  102. BAGHERI-YARMAND R, Williams MD, Grubbs EG, Gagel RF, et al
    ATF4 Targets RET for Degradation and is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Dec 9:jc20162878.
    PubMed     Abstract available


  103. MATRONE A, Gambale C, Piaggi P, Viola D, et al
    Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation.
    J Clin Endocrinol Metab. 2016 Dec 8:jc20162860.
    PubMed     Abstract available


    November 2016
  104. SCHNEIDER TC, de Wit D, Links TP, van Erp NP, et al
    Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.
    J Clin Endocrinol Metab. 2016 Nov 21:jc20162525.
    PubMed     Abstract available


  105. EHLERS M, Kuebart A, Hautzel H, Enczmann J, et al
    Epitope-specific antitumor immunity suppresses tumor spread in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 18:jc20162469.
    PubMed     Abstract available


  106. MAROTTA V, Sciammarella C, Capasso M, Testori A, et al
    Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 16:jc20162555.
    PubMed     Abstract available


  107. SUNG TY, Jeon MJ, Lee YH, Lee YM, et al
    Initial and Dynamic Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Nov 3:jc20162666.
    PubMed     Abstract available


    October 2016
  108. WANG W, Kang H, Zhao Y, Min I, et al
    Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.
    J Clin Endocrinol Metab. 2016 Oct 18:jc20161999.
    PubMed     Abstract available


  109. ZHANG Y, Sui F, Ma J, Ren X, et al
    Positive Feedback Loops between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20161677.
    PubMed     Abstract available


  110. HWANGBO Y, Kim JM, Park YJ, Lee EK, et al
    Long-term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162287.
    PubMed     Abstract available


    September 2016
  111. KIM SW, Song SH, Lee HS, Noh WJ, et al
    Intraoperative Real-Time Localization of Normal Parathyroid Glands with Autofluorescence Imaging.
    J Clin Endocrinol Metab. 2016 Sep 20:jc20162558.
    PubMed     Abstract available


  112. UCHINO S, Ishikawa H, Miyauchi A, Hirokawa M, et al
    Age- and Gender-Specific Risk of Thyroid Cancer in Patients with Familial Adenomatous Polyposis.
    J Clin Endocrinol Metab. 2016 Sep 13:jc20162043.
    PubMed     Abstract available


    August 2016
  113. YU XU J, Handy B, Michaelis CL, Waguespack SG, et al
    Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 30:jc20162567.
    PubMed     Abstract available


  114. ROBINSON B, Schlumberger M, Wirth LJ, Dutcus CE, et al
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 22:jc20153989.
    PubMed     Abstract available


  115. HOLLINGSWORTH B, Senter L, Zhang X, Brock GN, et al
    Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2016 Aug 17:jc20161605.
    PubMed     Abstract available


  116. PALERMO A, Mangiameli G, Tabacco G, Longo F, et al
    PTH(1-34) for the primary prevention of post-thyroidectomy hypocalcemia: the THYPOS trial.
    J Clin Endocrinol Metab. 2016 Aug 15:jc20162530.
    PubMed     Abstract available


  117. LY S, Frates MC, Benson CB, Peters HE, et al
    Features and outcome of autonomous thyroid nodules in children: 31 consecutive patients seen at a single center.
    J Clin Endocrinol Metab. 2016 Aug 8:jc20161779.
    PubMed     Abstract available


  118. LABOURIER E
    Letter to the Editor: The Value of Molecular Testing for Effective Management of Patients With Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2016;101:L76-7.
    PubMed    


    July 2016
  119. LIYANARACHCHI S, Li W, Yan P, Bundschuh R, et al
    Genome-wide expression screening discloses long noncoding RNAs involved in thyroid carcinogenesis.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20161991.
    PubMed     Abstract available


  120. LUO J, Hendryx M, Manson JE, Liang X, et al
    Hysterectomy, oophorectomy and risk of thyroid cancer.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20162011.
    PubMed     Abstract available


    May 2016
  121. LAMARTINA L, Grani G, Biffoni M, Giacomelli L, et al
    Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 May 17:jc20161440.
    PubMed     Abstract available


    April 2016
  122. LAMARTINA L, Ippolito S, Danis M, Bidault F, et al
    Anti-angiogenic Tyrosine Kinase Inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer.
    J Clin Endocrinol Metab. 2016 Apr 15:jc20154391.
    PubMed     Abstract available


  123. BASTMAN JJ, Serracino HS, Zhu Y, Koenig MR, et al
    Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Apr 5:jc20154227.
    PubMed     Abstract available


    March 2016
  124. MOMESSO DP, Vaisman F, Yang SP, Bulzico DA, et al
    DYNAMIC RISK STRATIFICATION IN DIFFERENTIATED THYROID CANCER PATIENTS TREATED WITHOUT RADIOACTIVE IODINE.
    J Clin Endocrinol Metab. 2016 Mar 29:jc20154290.
    PubMed     Abstract available


  125. BURCH HB, Burman KD, Cooper DS, Hennessey JV, et al
    A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules.
    J Clin Endocrinol Metab. 2016 Mar 25:jc20161155.
    PubMed     Abstract available


  126. LAZAR L, Lebenthal Y, Segal K, Steinmetz A, et al
    Pediatric thyroid cancer: postoperative classifications and response-to-initial-therapy as prognostic factors.
    J Clin Endocrinol Metab. 2016 Mar 1:jc20153960.
    PubMed     Abstract available


    February 2016
  127. AHN D, Ho Sohn J, Han Jeon J
    Hypothyroidism following hemithyroidectomy: incidence, risk factors, and clinical characteristics.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153997.
    PubMed     Abstract available


  128. BIKAS A, Schneider M, Desale S, Atkins F, et al
    Effects of Dosimetrically-Guided I-131 Therapy on Hematopoiesis in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153544.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: